Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
97% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. ALNY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALNY' s Cash to Debt Range Over the Past 10 Years
Min: 3.29  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
ALNY's Equity to Asset is ranked higher than
85% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALNY: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
ALNY' s Equity to Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.59 Max: 0.92
Current: 0.9
-0.99
0.92
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
98% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 20.43
M-Score: -3.09
WACC vs ROIC
17.94%
-118.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1183.13
ALNY's Operating margin (%) is ranked lower than
79% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. ALNY: -1183.13 )
Ranked among companies with meaningful Operating margin (%) only.
ALNY' s Operating margin (%) Range Over the Past 10 Years
Min: -800.97  Med: -164.88 Max: -28.95
Current: -1183.13
-800.97
-28.95
Net-margin (%) -1144.52
ALNY's Net-margin (%) is ranked lower than
79% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. ALNY: -1144.52 )
Ranked among companies with meaningful Net-margin (%) only.
ALNY' s Net-margin (%) Range Over the Past 10 Years
Min: -712.79  Med: -143.70 Max: -27.3
Current: -1144.52
-712.79
-27.3
ROE (%) -25.62
ALNY's ROE (%) is ranked higher than
56% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. ALNY: -25.62 )
Ranked among companies with meaningful ROE (%) only.
ALNY' s ROE (%) Range Over the Past 10 Years
Min: -84.12  Med: -34.05 Max: -13.08
Current: -25.62
-84.12
-13.08
ROA (%) -23.45
ALNY's ROA (%) is ranked higher than
54% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ALNY: -23.45 )
Ranked among companies with meaningful ROA (%) only.
ALNY' s ROA (%) Range Over the Past 10 Years
Min: -48.05  Med: -21.88 Max: -5.01
Current: -23.45
-48.05
-5.01
ROC (Joel Greenblatt) (%) -1288.69
ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ALNY: -1288.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2120.98  Med: -430.03 Max: -149.42
Current: -1288.69
-2120.98
-149.42
Revenue Growth (3Y)(%) -28.30
ALNY's Revenue Growth (3Y)(%) is ranked lower than
77% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ALNY: -28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -5.90 Max: 108
Current: -28.3
0
108
EBITDA Growth (3Y)(%) 11.20
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ALNY: 11.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: -4.20 Max: 65.3
Current: 11.2
-64.8
65.3
EPS Growth (3Y)(%) 17.90
ALNY's EPS Growth (3Y)(%) is ranked higher than
75% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ALNY: 17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.8  Med: 1.80 Max: 52.8
Current: 17.9
-66.8
52.8
» ALNY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ALNY Guru Trades in Q2 2015

Jim Simons 102,399 sh (New)
Pioneer Investments 630,129 sh (+29.97%)
John Griffin 1,075,000 sh (+11.98%)
Mairs and Power 2,200 sh (unchged)
Vanguard Health Care Fund 6,094,810 sh (unchged)
Julian Robertson Sold Out
Columbia Wanger Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2015

ALNY Guru Trades in Q3 2015

Vanguard Health Care Fund 7,355,914 sh (+20.69%)
Pioneer Investments 632,698 sh (+0.41%)
John Griffin 1,075,000 sh (unchged)
Jim Simons Sold Out
Mairs and Power Sold Out
» More
Q4 2015

ALNY Guru Trades in Q4 2015

Mairs and Power 2,300 sh (New)
George Soros 6,000 sh (New)
John Paulson 12,300 sh (New)
Vanguard Health Care Fund 7,583,610 sh (+3.10%)
John Griffin 1,075,000 sh (unchged)
Pioneer Investments Sold Out
» More
Q1 2016

ALNY Guru Trades in Q1 2016

Jim Simons 214,000 sh (New)
Vanguard Health Care Fund 8,512,270 sh (+12.25%)
John Paulson 12,300 sh (unchged)
John Griffin 1,075,000 sh (unchged)
George Soros Sold Out
Mairs and Power Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:UTHR, NAS:ANAC, OTCPK:SBMFF, NAS:JUNO, NAS:TECH, NAS:OPK, NAS:SGEN, OTCPK:BTGGF, NAS:DYAX, NAS:ACAD, NAS:ICPT, NAS:ALKS, OTCPK:LBTSF, NYSE:XON, NAS:CBPO, NAS:IONS, OTCPK:SOLTF, NAS:KITE, NAS:LGND, NAS:GLPG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" - the molecules that mediate RNAi - toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include paten, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.

Ratios

vs
industry
vs
history
P/B 3.96
ALNY's P/B is ranked lower than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ALNY: 3.96 )
Ranked among companies with meaningful P/B only.
ALNY' s P/B Range Over the Past 10 Years
Min: 2.07  Med: 4.82 Max: 21.37
Current: 3.96
2.07
21.37
P/S 157.06
ALNY's P/S is ranked lower than
89% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. ALNY: 157.06 )
Ranked among companies with meaningful P/S only.
ALNY' s P/S Range Over the Past 10 Years
Min: 3.09  Med: 20.44 Max: 220.57
Current: 157.06
3.09
220.57
Current Ratio 15.82
ALNY's Current Ratio is ranked higher than
86% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALNY: 15.82 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.75 Max: 18.24
Current: 15.82
1.88
18.24
Quick Ratio 15.82
ALNY's Quick Ratio is ranked higher than
86% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ALNY: 15.82 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.75 Max: 18.24
Current: 15.82
1.88
18.24
Days Sales Outstanding 107.58
ALNY's Days Sales Outstanding is ranked lower than
76% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ALNY: 107.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 107.58
0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.37
ALNY's Price/Net Cash is ranked higher than
51% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. ALNY: 5.37 )
Ranked among companies with meaningful Price/Net Cash only.
ALNY' s Price/Net Cash Range Over the Past 10 Years
Min: 3.7  Med: 8.97 Max: 92.77
Current: 5.37
3.7
92.77
Price/Net Current Asset Value 5.15
ALNY's Price/Net Current Asset Value is ranked higher than
50% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. ALNY: 5.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALNY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.54  Med: 8.79 Max: 82.06
Current: 5.15
3.54
82.06
Price/Tangible Book 4.00
ALNY's Price/Tangible Book is ranked higher than
51% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. ALNY: 4.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ALNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.2  Med: 4.90 Max: 15.16
Current: 4
2.2
15.16
Price/Median PS Value 7.68
ALNY's Price/Median PS Value is ranked lower than
96% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. ALNY: 7.68 )
Ranked among companies with meaningful Price/Median PS Value only.
ALNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 0.96 Max: 9.29
Current: 7.68
0.16
9.29
Earnings Yield (Greenblatt) (%) -9.45
ALNY's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ALNY: -9.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.16  Med: 465.90 Max: 1781.6
Current: -9.45
-10.16
1781.6

More Statistics

Revenue (TTM) (Mil) $29.91
EPS (TTM) $ -4.04
Beta2.16
Short Percentage of Float12.39%
52-Week Range $49.96 - 137.89
Shares Outstanding (Mil)85.56

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 45 65 199
EPS ($) -5.14 -5.61 -1.53
EPS w/o NRI ($) -5.14 -5.61 -1.53
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ALNY

Headlines

Articles On GuruFocus.com
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 

More From Other Websites
Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on... Jun 27 2016
Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on... Jun 27 2016
Cramer: Investors will freak out over this stock's European business Jun 24 2016
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping... Jun 23 2016
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual... Jun 23 2016
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 15 2016
Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US :... Jun 13 2016
Alnylam Pharmaceuticals Inc Conference Call to Discuss Phase 1/2 Clinical Results with ALN-CC5... Jun 11 2016
Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)... Jun 11 2016
Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)... Jun 11 2016
ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : June 9, 2016 Jun 09 2016
IBB Holdings: How Are Their Moving Averages Trending? Jun 09 2016
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for... Jun 09 2016
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for... Jun 09 2016
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data Jun 03 2016
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data Jun 03 2016
​Alnylam gains a cool $1.5B in market cap on bad news for rival Jun 02 2016
Alkermes Rises on Evercore’s ‘Buy’ Rating, Buying Support Jun 01 2016
How to Discover the Best Biotechs in the World May 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)